Premium
A HEAD‐TO‐HEAD PHASE 3 STUDY COMPARING BGB‐3111 AND IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
Author(s) -
Buske C.,
LeBlond V.,
Novotny W.,
Owen R.,
Tedeschi A.,
Atwal S.,
Cohen A.,
Huang J.,
Tam C.S.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2440_5
Subject(s) - ibrutinib , bruton's tyrosine kinase , waldenstrom macroglobulinemia , medicine , macroglobulinemia , cancer research , kinome , tyrosine kinase , oncology , immunology , lymphoma , kinase , leukemia , receptor , biology , chronic lymphocytic leukemia , multiple myeloma , microbiology and biotechnology